Lindsay Androski - 02 Feb 2026 Form 4 Insider Report for Arbutus Biopharma Corp (ABUS)

Role
President and CEO, Director
Signature
/s/ Tuan Nguyen as attorney-in-fact for Lindsay Androski
Issuer symbol
ABUS
Transactions as of
02 Feb 2026
Net transactions value
$0
Form type
4
Filing time
02 Feb 2026, 20:21:13 UTC
Previous filing
20 Mar 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Androski Lindsay President and CEO, Director C/O ARBUTUS BIOPHARMA CORPORATION, 701 VETERANS CIRCLE, WARMINSTER /s/ Tuan Nguyen as attorney-in-fact for Lindsay Androski 02 Feb 2026 0001936604

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABUS Common Shares Award $0 +28,000 $0.000000 28,000 02 Feb 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABUS Stock Option (Right to Buy) Award $0 +71,700 $0.000000 71,700 02 Feb 2026 Common Shares 71,700 $4.39 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction.
F2 Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant.
F3 This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date.